Menu
Back to Journals » Journal of Multidisciplinary Healthcare » Volume 16
Profiles of Independent-Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals [Response to Letter]
Authors Said KB , Alsolami A, Alreshidi FS, Fathuddin A, Alshammari F, Alrashid F, Aljadani A, Aboras R, Alreshidi F, Alghozwi MH, Alshammari SF, Alharbi NF
Received 29 May 2023
Accepted for publication 8 June 2023
Published 9 June 2023 Volume 2023:16 Pages 1617—1618
Kamaleldin B Said,1,2 Ahmed Alsolami,3 Fayez Saud Alreshidi,4 Anas Fathuddin,5 Fawwaz Alshammari,6 Fauwaz Alrashid,7 Ahmed Aljadani,3 Rana Aboras,4 Fatmah Alreshidi,4 Mohammed H Alghozwi,1 Suliman F Alshammari,1 Nawaf F Alharbi1
1Department of Pathology and Microbiology, College of Medicine, University of Ha’il, Ha’il, 55476, Saudi Arabia; 2Genomics, Bioinformatics and Systems Biology, Carleton University, Ottawa, ON, K1S 5B6, Canada; 3Department of Internal Medicine, College of Medicine, University of Ha’il, Ha’il, 55476, Saudi Arabia; 4Deparmtent of Family, Community Medicine, College of Medicine, University of Ha’il, Ha’il, 55476, Saudi Arabia; 5Department of Plastic Surgery, College of Medicine, University of Ha’il, Ha’il, 55476, Saudi Arabia; 6Department of Dermatology, College of Medicine, University of Ha’il, Ha’il, 55476, Saudi Arabia; 7Department of Surgery, College of Medicine, University of Ha’il, Ha’il, 55476, Saudi Arabia
Correspondence: Kamaleldin B Said, Department of Pathology and Microbiology, College of Medicine, University of Ha’il, Ha’il, 55476, Saudi Arabia, Tel +966500771459, Email [email protected]
View the original paper by Dr Said and colleagues
This is in response to the Letter to the Editor
Dear editor
We would like to submit a response to the Letter to the Editor, by: Sri Wahyuni Gayatri; Andi St Fahirah Arsal; Wisdawan on the Article: Said et al, Profiles of Independent Comorbidity Groups in Senior COVID-19 Patients Reveal Low Fatality Associated with Standard Care and Low-Dose Hydroxychloroquine over Antivirals.
We thank the authors of Letter to the Editor for their positive comments and interests in the article and in their comments helping to promote research in this vital area. All safety protocols were carefully applied for the best possible outcome. We agree with the authors of the Letter on the availability of published data about favipiravir superior safety regarding toxicity in comorbid COVID-19 patients suffering from heart disease. However, initial global COVID-19 treatment protocols were constantly under scrutiny for best options; for instance, with regard to HQC. In this circumstance and before we discontinued, HQC and other antivirals treatments were administered independently on independent comorbidity groups, each drug was monitored on groups that were safe for it, and HQC was first administered at a safe low level then gradually titrated to a slightly higher but safer concentrations with positive outcome before discontinued based on global recommendations. The authors of the Letter briefly touched on the mechanisms of HQC, while the pH-based mechanism has been widely known, there has been enormous efforts at different stages on validating specific molecular mechanisms.
In conclusion, we again thank the authors of the Letter to the Editor for their interest, comments, and additional recommendations in this area.
Disclosure
The authors declare no conflicts of interest in this communication.
© 2023 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.